Financings Of The Fortnight Looks Ahead To The Annual Survey Of Life Sciences Venture Capital Firms
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financing activity by Novira Therapeutics, MediciNova, Elcelyx Therapeutics and Relypsa.
You may also be interested in...
Relypsa Adds Venture Funds In Another Effort To Reach Phase III
Relypsa, spun out from Amgen in 2007, has raised a third round of financing in an effort to move its lead compound into late-stage development.
START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In
In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.